Cardiac monitoring company PaceMate has announced the appointment of JR Finkelmeier as its new chief executive officer (CEO).
Finkelmeier joined PaceMate as chief commercial officer in 2024 after years leading Philips’ ambulatory monitoring division. Now, as CEO of PaceMate, he will lead the company through operational transformation in support of plans for significant commercial expansion, as stated in a press release. Finkelmeier succeeds founding CEO Tripp Higgins, who will become the chairman of the board of directors.
“I’m honoured to take on this role and continue building on the strong foundation Tripp has created,” said Finkelmeier. “PaceMate realised before anyone else that, with complex cardiac data spread across disparate systems, data gathering is at odds with delivering the best patient care. The company spent a decade building the ideal platform to solve this challenge. PaceMate’s original mission to improve outcomes through real-time cardiac monitoring is more vital now than ever. I look forward to leading the company forward as it delivers connected cardiac care to more providers and patients around the world.”
PaceMate’s recent release goes on to detail that, since its founding 10 years ago, the company has achieved widespread adoption by healthcare providers like Duke Health, Advocate Health and many others.
In 2024, PaceMate acquired Medtronic’s PaceArt Optima system, adding nearly 1,000 more clinic locations and making it—as claimed by PaceMate—“the only company” that can fully convert and transfer the full spectrum of in-person and historical PaceArt patient data. Now, with more than two million patients under management and more health systems than ever looking to migrate legacy monitoring systems to the cloud, PaceMate says it is focused on pairing a decade of product innovation with the operational scale needed to meet the growing demands of modern cardiac care.
It is against this backdrop that Finkelmeier will set out to “significantly expand” PaceMate’s operational readiness to scale delivery across its fast-growing customer base. Among his immediate priorities are meeting demand for the company’s core platform, PaceMateLIVE, and continued investment in the company’s artificial intelligence (AI) tech-enabled clinical capabilities and certified cardiac expertise.
“From the beginning, our goal has been to build a platform that eliminates the unnecessary challenges created by traditional remote monitoring approaches, so clinicians can provide their patients with the best care possible,” said Higgins. “We translated the real-world problems that care teams face into a platform that significantly streamlines their workflows, expedites time to clinical care and intelligently prioritises patients. Now, JR brings the growth expertise necessary to take PaceMate to the next level, ensuring that our platform reaches its full potential.”
